Targeting PI3K Pathway
- Read the following information before beginning the educational activity and click the "Continue" link at the bottom of the page.
- View the educational activity.
- Complete the CME post-test and evaluation.
- After successful completion of the CME post-test and evaluation, you will receive the credit or participation certificate
*The CME post-test and evaluation must be completed by May 4, 2022 in order to receive the credit or participation certificate.
Physicians who wish to advance their current knowledge of PI3K pathway in cancer biology and its clinical impact.
- Understand the role of PI3K pathway in cancer biology and the clinical impact of available therapeutics targeting this pathway.
- Learn about tissue and plasma-based testing strategies for PI3K-activating mutations
- Learn about the most common adverse events associated with PI3K pathway inhibitors and their management
Accreditation and Credit Designation
The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.
The Society for Translational Oncology designates this CME activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
It is the policy of the Society for Translational Oncology (STO) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities through the disclosure of financial interests and other relationships. As an education provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), STO must comply with the ACCME Standards for Integrity and Independence.
In accordance with the policy of STO, all persons in a position to control the content of a CME activity must disclose any financial relationships with ineligible companies occurring within the last 24 months. STO abides by a policy of anonymous peer review: disclosure of any financial relationships with ineligible companies/commercial interests will be reviewed by the CME Activity Directors with the ad hoc assistance of external reviewers; any conflicts of interest found will be mitigated prior to the activity.
Dejan Juric, MD
Scientific advisory board fees: Eisai, EMD Serono, Genentech, Ipsen, Novartis, Guardant, Syros, Petra Pharma, Relay Therapeutics, Vibliome, MapKure, PIC Therapeutics
Research funding (to the institution): Novartis, Genentech, EMD Serono, Eisai, Takeda, Placon Therapeutics, Syros, Ribon, Infinity, InventisBio, Arvinas
Bruce Chabner, M.D.
EMD Serono, Cyteir, Eli Lilly & Co., Boston Pharmaceuticals, Chugai Pharmaceuticals.
Aditya Bardia, M.D., MPH
Advisory role with Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Diiachi Pharma/Astra Zeneca, Puma Biotechnology, Biothernostics Inc., Phillips, Eli Lilly, Foundation Medicine.
Research funding from BGenentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Diiachi Pharma/Astra Zeneca.
CME Program Editor Disclosures
Jayne S. Gurtler, M.D., F.A.C.P.
No financial relationships relevant to the content of this activity have been disclosed.
Staff Planners Disclosures
No financial relationships relevant to the content of this actvity have been disclosed by the staff planners.
This activity was funded in part through educational grants from Novartis Pharmaceuticals Corp. and Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
STO CME online supports the following browsers: current production versions of Safari, Firefox, Chrome and Explorer. Mobile devices with iOS and Android operating systems are also supported.
Society for Translational Oncology
318 Blackwell Street, Suite 270
Durham, North Carolina 27701
Phone: (919) 433-0489
Fax: (919) 680-4411